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ABSTRACT
Purpose To study the influence of protein aggregation on the
immunogenicity of recombinant human interferon beta
(rhIFNβ) in wild-type mice and transgenic, immune-tolerant
mice, and to evaluate the induction of immunological memory.
Methods RhIFNβ-1b and three rhIFNβ-1a preparations with
different aggregate levels were injected intraperitoneally in mice
15× during 3 weeks, and the mice were rechallenged with
rhIFNβ-1a. The formation of binding (BABs) and neutralizing
antibodies (NABs) was monitored.
Results Bulk rhIFNβ-1a contained large, mainly non-covalent
aggregates and stressed rhIFNβ-1a mainly covalent, homoge-
neous (ca. 100 nm) aggregates. Reformulated rhIFNβ-1a was
essentially aggregate-free. All products induced BABs and
NABs in wild-type mice. Immunogenicity in the transgenic
mice was product dependent. RhIFNβ-1b showed the highest
and reformulated rhIFNβ-1a the lowest immunogenicity. In
contrast with wild-type mice, transgenic mice did not show
NABs, nor did they respond to the rechallenge.
Conclusions The immunogenicity of the products in trans-
genic mice, unlike in wild-type mice, varied. In the transgenic
mice, neither NABs nor immunological memory developed.
The immunogenicity of rhIFNβ in a model reflecting the
human immune system depends on the presence and the
characteristics of aggregates.
KEY WORDS antibodies.immunogenicity.immunological
memory.proteinaggregates.recombinanthumaninterferon
beta
ABBREVIATIONS
BABs binding antibodies
ECD equivalent circular diameter
hIFNβ human interferon β
HSA human serum albumin
IgG immunoglobulin G
i.p. intraperitoneally
MxA myxovirus resistant protein A
NABs neutralizing antibodies
PDI polydispersity index
rhIFNβ recombinant human interferon beta
rhIFNβ-1a recombinant human interferon beta-1a
rhIFNβ-1b recombinant human interferon beta-1b
RR-MS relapsing-remitting multiple sclerosis
SDS sodium dodecyl sulfate
TRU/ml ten-fold reduction units per ml
INTRODUCTION
The ability of biopharmaceuticals to elicit an undesirable
immune response in patients is a major concern. Despite
the development of recombinant therapeutic homologues to
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patients (1,2). In general, antibodies against recombinant
human therapeutic products only appear after prolonged
treatment. They can have an effect on the clearance of the
drug, decrease its therapeutic efficacy, or may lead to
immune complex-related diseases such as anaphylaxis and
serum sickness (3). Occasionally, antibodies cross-react with
the endogenous homologous protein, leading tosevere clinical
consequences, e.g. in the case of epoetin (4). An example of a
therapeutic protein with high clinical immunogenicity is
recombinant human interferon beta-1b (rhIFNβ-1b).
The rhIFNβs are considered first-line disease-modifying
therapies of relapsing-remitting forms of multiple sclerosis.
They reduce relapse rates and brain lesions. A substantial
proportion of relapsing-remitting multiple sclerosis (RR-MS)
patients shows a decline in response over time, which can be
attributed to the formation of neutralizing antibodies
(NABs). This immunological response generally starts with
the appearance of BABs after approximately 9 to 18 months
of treatment, followed by NABs (5). Neutralizing antibodies
against rhIFNβ are tested in assays based on the inhibition
of a cellular response to human interferon beta.
All four commercial rhIFNβ products, Betaferon/
Betaseron® (Schering, Berlin, Germany and Berlex
Laboratories, Montville, New Jersey, USA), Avonex®
(Biogen Idec, Cambridge, Massachusetts, USA), Rebif®
(Serono, Geneva, Switzerland) and Extavia® (Novartis,
Basel, Switzerland), show immunogenicity in patients, but
the level of BABs and NABs varies among the products
(6). The products differ with respect to formulation, and
route and frequency of administration. Moreover, Avo-
nex® and Rebif® (both rhIFNβ-1a) are glycosylated,
produced in CHO cells and have amino acid sequences
corresponding to that of natural hIFNβ, whereas Extavia®
and Betaferon® (both rhIFNβ-1b) are produced in E. coli,
are not glycosylated and have a slightly different amino acid
sequence (Cys-17 is mutated to Ser-17, and the N-terminal
methionine is deleted (7)). These product differences appar-
entlyaffectimmunogenicity.Likely,thelowersolubilitydueto
the lack of glycosylation results in aggregation causing a high
immunogenicity of rhIFNβ-1b (6,7). Whether the relatively
low immunogenicity of rhIFNβ-1a products is also associated
with aggregates is unknown.
Structure and formulation of the protein as well as
degree of aggregation and aggregate characteristics are
generally recognized as important factors influencing the
immunogenicity of therapeutic proteins (1,8,9). The immu-
nogenicity of recombinant human interferon alpha was
related to the level of aggregation (10). Also, clinical data
with other therapeutic proteins, such as intravenous immune
globulin, human growth hormone and interleukin-2, strongly
suggest a direct correlation between aggregate levels and
immunogenicity (11).
Transgenic, immune-tolerant mouse models are valuable
tools to study the influence of product-related factors such
asaggregation onimmunogenicity(8,12,13). Wild-type mice
recognize recombinant human proteins as foreign and
consequently exhibit a classical immune response. Mice
transgenic for a specific human protein are, like humans,
immune tolerant for this protein and provide the opportu-
nity to study the factors that break immune tolerance. In
addition, these mice enable us to study the immunological
mechanism by which the antibodies to therapeutic proteins
are induced. A classical immune response against a foreign
protein leads to immunological memory, resulting in an
enhanced response after rechallenge with that protein (14).
Observations in patients producing antibodies to therapeu-
tic proteins, who are retreated after a washout period,
suggest a low level or even lack of memory response (15,16).
In this work, rhIFNβ-1a samples with different aggregate
levels were prepared and characterized. The immunoge-
nicity of these samples was compared with that of rhIFNβ-
1b. We tested immunogenicity by measuring BAB and
NAB levels after repetitive administration and a rechallenge
with rhIFNβ-1a in our hybrid hIFNβ transgenic, immune-
tolerant mouse model (17). The aims of this study were to
investigate the influence of aggregation on the immunoge-
nicity of rhIFNβ-1a and to evaluate the formation of
antibodies and the induction of immunological memory for
the protein in wild-type mice and transgenic, immune-
tolerant mice.
MATERIALS AND METHODS
RhIFNβ Products
Bulk rhIFNβ-1awas supplied by Biogen IdecInc. (Cambridge,
M A ,U S A )a sa0 . 2 7m g / m ls o l u t i o ni n1 0 0m Ms o d i u m
phosphate buffer and 200 mM sodium chloride at pH 7.2.
Reformulated rhIFNβ-1a was produced by dialysis of bulk
rhIFNβ-1a with a 3.5 kDa MWCO Slide-A-Lyzer Cassette
(Perbio Science, Etten-Leur, the Netherlands) against a
commercially used formulation containing 20 mM sodium
acetate buffer, 150 mM L-arginine monohydrochloride and
0.04 mM Tween 20 (Sigma Aldrich, Zwijndrecht, the
Netherlands) at pH 4.8 (18), and subsequent filtration
through a 0.22 μm polyethersulfone membrane (Millipore,
Amsterdam, the Netherlands). The resulting protein concen-
tration was determined by UV absorbance measurements at
λ = 280 nm with an extinction coefficient (E1cm
0:1%) of 1.5. This
value was calculated from the molar mass of rhIFNβ-1a
(20,027.78 Da) without carbohydrate chain and its molar
extinction coefficient (29,990 Lmol
−1cm
−1) based on amino
a c i d( T r p ,T y r ,P h ea n dd i s u l f i d e )c o m p o s i t i o n( 19). Biogen
Idec Inc. supplied stressed rhIFNβ-1a produced by incubating
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one hour at pH 2.1 in the presence of 1 M sodium chloride.
After incubation, the solution had been neutralized to pH 7.1
and run over a Superose 12 size-exclusion column to isolate
soluble aggregates. This resulted in 0.109 mg/ml stressed
rhIFNβ-1a in a buffer of 8 mM dibasic sodium phosphate,
1.5 mM monobasic potassium phosphate, 137 mM sodium
chloride and 2.7 mM potassium chloride at pH 7.1.
Betaferon® (Schering, Berlin, Germany) was obtained from
local hospitals and contained 0.25 mg/ml rhIFNβ-1b with
human serum albumin (HSA), mannitol and sodium chloride
after reconstitution of the lyophilized powder according to the
manufacturer’s instructions.
Characterization of rhIFNβ-1a Structural Variants
Visual Inspection
Samples were inspected visually at the lab bench against a
black background and compared with water as a control.
UV Spectroscopy
UV spectra (λ =1 9 0 –1,100 nm) of the samples were
recorded at 25°C on an Agilent 8453 UV/VIS spectropho-
tometer in quartz cuvettes with a path length of 1 cm.
Samples were diluted with the corresponding buffer to a
concentration of 100 μg/ml rhIFNβ-1a and measured in the
presence or absence of 0.01% (w/v) sodium dodecyl sulfate
(SDS). The corresponding sample buffer was used as a blank.
Dynamic Light Scattering (DLS)
Samples were analyzed with dynamic light scattering (DLS)
to obtain an average diameter of the particles (Z-ave) and
their polydispersity index (PDI). A Malvern Zetasizer Nano
ZS apparatus equipped with a red laser (λ = 633 nm), a
detector at 173° and Dispersion Technology Software
version 4.20 was used. Samples were diluted with the
corresponding buffer to a concentration of 100 μg/ml
rhIFNβ-1a and measured in the presence or absence of
0.01% (w/v) SDS.
Flow Microscopy
Particulate matter in 50 μg/ml rhIFNβ-1a samples and the
corresponding buffers was measured with a Micro-Flow
Imaging instrument type DPA4100 (Brightwell Technolo-
gies, Inc., Canada). A high magnification setting allowed
the detection of particles in the range of 0.75 to 70 μm with
an analysis field depth of 100 μm. Prior to each run, Milli-
Q water filtered through a 0.22 μm filter was flushed
through the system to provide a clean background and to
optimize illumination. To equilibrate the system, 0.2 ml of
sample was dispensed before analysis. Samples were drawn
from a 1 ml pipette tip at a flow rate of 100 μL/min using a
peristaltic pump and analyzed for 5 minutes. Particle size was
measured as the equivalent circular diameter (ECD) repre-
senting the diameter of a circle occupying the same projection
area as the particle. Aspect ratios (the ratio of the longest
dimension to the perpendicular dimension at the midpoint)
were derived from 200 images stored during one run.
Fluorescence Spectroscopy
Fluorescence emission spectra of 50 μg/ml samples were
measured at 25°C from 310 to 410 nm with 1 nm steps
in quartz cuvettes with a path length of 1 cm while
stirring. An Edinburgh Instruments Steady State FS 920
fluorimeter was used. Samples were excited at 295 nm,
and slits were set at 3 nm. Dwell time per data point was
0.5 s, and the sum of three scans was taken. The
corresponding buffer spectra were subtracted. Emission
maxima were determined with the FS 900 fluorescence
spectrometer software.
High-Performance Size-Exclusion Chromatography (HP-SEC)
Samples (100 μg/ml) were analyzed with a TSKgel Super
SW2000 column and Super SW guard column (Sigma
Aldrich),andchromatogramswererecordedwithaShimadzu
SPD-6AV UV detector. A Waters 515 HPLC pump and 717
Plusautosamplerwereoperatedataflowrateof0.35ml/min.
The mobile phase consisted of 100 mM sodium phosphate
buffer, 200 mM sodium chloride, 0.05% (w/v) sodium azide
and 0.1%(w/v)SDSata pHof7.2 and wasfilteredthrough a
0.2 μm filter prior to use.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS-PAGE)
Pre-cast gels (Ready Gels, Tris-HCl, linear gradient 4–
20%, Biorad, Veenendaal, the Netherlands) were run
under non-reducing and reducing (sample buffer containing
5% (v/v) β-mercaptoethanol) conditions at 200 V at room
temperature. Samples analyzed under reducing conditions
were heated at 99°C for five minutes before applying to the
gel. A volume of 10 μl of undiluted sample with 10 μlo f
sample buffer was applied to each well. Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was
performed with a Biorad Mini-Protean 3 module. The
electrophoresis buffer was 25 mM tris (hydroxymethyl)
aminomethane, 192 mM glycine and 0.1% (w/v) SDS. Pre-
stained broad range molecular weight markers (Biorad)
were included for molecular weight determination, and a
Silver Stain Plus kit (Biorad) was used to visualize the
1814 van Beers et al.protein bands. The gels were scanned with a Biorad GS-
800 densitometer and Quantity One software.
Western Blotting
SDS-PAGE gels were blotted onto a nitrocellulose sheet
(VWR International, Amsterdam, the Netherlands) with a
Biorad Mini Trans-Blot electrophoretic transfer cell and a
transfer buffer containing 10 mM sodium hydrogen
carbonate, 3 mM sodium carbonate, 20% (v/v) methanol
and 0.1% SDS (w/v) at pH 10.0. Blots were blocked
overnight at 4°C with 8% (w/v) non-fat milk powder (ELK,
Campina Melkunie, Eindhoven, the Netherlands) in
0.005% (w/v) Tween 20 in phosphate-buffered saline
(PBS, consisting of 3.6 mM KH2PO4, 6.4 mM Na2HPO4
and 145 mM NaCl at pH 7.2) with constant orbital
shaking. After washing with 0.005% (w/v) Tween 20 in
PBS, the blots were incubated with 0.2 μg/ml polyclonal
rabbitanti-rhIFNβantibody(AcrisAntibodies,Hiddenhausen,
Germany) in 0.1% (w/v) non-fat milk powder and 0.005%
(w/v) Tween 20 in PBS for one hour at room temperature
with constant orbital shaking. Blots were washed with
0.005% (w/v) Tween 20 in PBS. Blots were incubated
with peroxidase-labeled goat anti-rabbit immunoglobulin G
(IgG) (Sigma Aldrich), diluted 1000-fold in PBS containing
0.1% (w/v) non-fat milk powder and 0.005% (w/v) Tween
20, for one hour at room temperature with constant orbital
shaking. Blots were washed with 0.005% (w/v) Tween 20 in
PBS and incubated in a solution of 0.05% (w/v) 4-chloro-1-
naphtol (Sigma-Aldrich) in 17% (v/v) methanol and
0.0125% (v/v) H2O2. After color development, the blots
were stored overnight in the dark in water to increase the
intensity of the bands.
Immunogenicity Study
Mouse Breeding
Heterozygous C57Bl/6 transgenic mice immune tolerant
for hIFNβ, developed by Hermeling et al.( 20), were bred at
theCentral LaboratoryAnimalInstitute(UtrechtUniversity,
the Netherlands). The strain was maintained by crossing the
transgenics with wild-type C57Bl/6 mice obtained from
Janvier (Bioservices, Uden, the Netherlands). The genotype
of the offspring was determined by PCR showing the
presence or absence of the hIFNβ gene in chromosomal
DNA isolated from ear tissue. Transgenic C57Bl/6 mice
were crossed with wild-type FVB/N mice obtained from
Janvier (BioServices), and their C57Bl/6 × FVB/N hybrid
offspring were genotyped using PCR. Both transgenic
C57Bl/6 × FVB/N hybrid mice and their non-transgenic
(wild-type) littermates, evaluated previously as a mouse
model for human interferon beta (17), were used.
Animal Experiment
The animal experiments were approved by the Institutional
Ethical Committee. Food (Hope Farms, Woerden, the
Netherlands) and water (acidified) were available ad libitum.
Blood was drawn from the cheek pouches (submandibu-
larly) of 32 wild-type and 32 transgenic mice before starting
the treatment (17,20). Eight mice per group were injected
intraperitoneally (i.p.) with 5 μg of bulk, reformulated or
stressed rhIFNβ-1a, or 5 μg of Betaferon®-rhIFNβ-1b on
days 0 to 4, days 7 to 11 and days 14 to 18. After an
injection-free period of 6 weeks, all mice were rechallenged
with 5 μg of reformulated rhIFNβ-1a i.p. on days 63 and
64. Blood was collected submandibularly from two out of
eight mice per group per time point, just before treatment
with rhIFNβ, on days 4, 7, 11, 14, 18, 21, 28, 43, 53, 56,
58, 60, 64, 65, 66 and 67. If administered rhIFNβ is not
completely cleared from the circulation before blood
drawing, remaining rhIFNβ levels could interfere with the
BAB assay. Therefore, we performed an additional study
following rhIFNβ blood levels in time with ELISA after a
single i.p. injection of 5 μg of Betaferon®-rhIFNβ-1b or
bulk rhIFNβ-1a in wild-type hybrid mice. From this study,
we estimated that the half-lives of rhIFNβ-1b and rhIFNβ-
1a in the mice were 2.5 and 4.5 hours, respectively. Since
the time interval between the previous dose and the blood
sampling on days 4, 11, 18, 64 and 65 was relatively short
(i.e. 20 to 24 hours), low levels of rhIFNβ-1a may have
remained in the plasma samples of these days. For the other
blood sampling days and for rhIFNβ-1b, most likely sufficient
time passed after the previous dose to allow for clearance of
the protein from the circulation. On day 77, all mice were
sacrificed by bleeding through cardiac punction under
isofluran anesthesia. Blood samples were collected in lithium
heparin gel tubes and centrifuged for 10 min at 3,000 g, and
the obtained plasma was stored at −80°C until analysis.
Binding Antibody Assay
Titers of BABs against rhIFNβ were measured in the
plasma by direct ELISA according to the protocol
described in detail by Hermeling et al.( 20) with minor
changes. Plates were coated with bulk rhIFNβ-1a and
blocked with 4% milk powder and 0.1% Tween 20 in PBS
at room temperature for two hours. Plasma samples and
the secondary antibody (horseradish peroxidase coupled
anti-mouse IgG from Invitrogen, Zymed) were diluted in
the blocking buffer described above in a ratio of 1:100 and
1:4000, respectively. Color conversion was initiated by
adding 100 μl of 3,3′,5,5′-tetramethylbenzidine (Roche)
and stopped by adding 100 μl of 0.18 M sulfuric acid.
Absorbance values were measured with an immuno plate
reader (Novopath, Biorad) at a wavelength of 450 nm. The
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positive if their mean absorbance values were at least three
times higher than the 95
th percentile value of negative
control plasma. The titer of anti-hIFNβ IgG in positive
plasma was determined by plotting the absorbance values
of a 2-fold serial dilution against log dilution. The plots
were fitted to a sigmoidal dose-response curve using
GraphPad Prism version 4.0 for Windows (GraphPad
Software, San Diego CA, USA). The reciprocal of the
dilution of the EC50 value was defined as the BAB titer.
Neutralizing Antibody Assay
NAB levels in the plasma samples of day 77 were assessed
in a bioassay based on inhibition of induction of myxovirus
resistance protein A (MxA) gene expression in an A549 cell
line as previously described (21). The type of rhIFNβ (−1a
or −1b) used in the assay was the same as the type used for
injecting the animal. Both MxA and a control household
gene-derived mRNA (eukaryotic 18S rRNA) were detected
with a real-time RT-PCR multiplex assay. Neutralizing
activity was expressed in ten-fold reduction units per ml
(TRU/ml). Plasma samples with a neutralizing activity
below 130 TRU/ml were considered negative. Positive
samples showed neutralizing activities ranging from 1143
TRU/ml to more than 5120 TRU/ml.
RESULTS AND DISCUSSION
Characterization of rhIFNβ-1a Structural Variants
Visual Inspection
ThethreerhIFNβ-1asolutionswerecolorlessandtransparent,
and visual inspection did no reveal visible aggregation or
precipitation.
UV Spectroscopy
All UV spectra showed broad absorbance peaks around the
wavelength of 280 nm, indicating tryptophan, tyrosine or
phenylalanine residues or disulfide bonds in the rhIFNβ-1a
samples (Fig. 1A)( 22,23). Protein aggregates cause scattering
of light that can be observed as an increase in optical density
(OD) (23). The wavelength-dependent light scattering inten-
sity is influenced by several factors, such as aggregate size,
shape and amount. As a measure for aggregation, the OD at
350 nm (OD350) and the ratio between the OD at 280 nm
and 260 nm (OD280/OD260) were used (Table I). As
compared with reformulated rhIFNβ-1a (OD350=0.02;
OD280/OD260 = 1.67), bulk and stressed rhIFNβ-1a
showed a high OD350 (0.11 and 0.08, respectively) and a
low OD280/OD260 (1.12 and 1.01), indicating the presence
of aggregates (Table I). Light scattering at high wavelengths
was most pronounced in bulk rhIFNβ-1a, which suggests the
presence of large aggregates. Stressed rhIFNβ-1a showed the
lowest OD280/OD260, most likely caused by absorption
flattening due to extensive aggregation of the sample (23).
Aggregates of rhIFNβ formed by non-covalent protein
bonds can be disassembled by SDS (24). Adding 0.01%
SDS changed the UV spectrum of bulk rhIFNβ-1a
drastically (Fig. 1A). Its OD350 and A280/A260 became
similar to those of reformulated rhIFNβ-1a with SDS
(Table I), indicating non-covalently bound aggregates. In
contrast, the UV spectrum of stressed rhIFNβ-1a changed
only slightly after adding SDS, suggesting the presence of a
considerable amount of covalent aggregates. The initial
OD350 and OD280/OD260 values, together with the
marginal decrease in OD350 and increase in OD280/
OD260 following the addition of SDS suggest a low level of
non-covalent aggregates in reformulated rhIFNβ-1a.
Dynamic Light Scattering (DLS)
According to studies on rhIFNβ-1a crystals performed by
Karpusas et al., the protein has a cylindrical shape of
roughly 2×3×4 nm (25). Bulk rhIFNβ-1a showed a large
Z-ave (2,300 nm) and a large PDI (0.9), indicating that the
sample contained aggregates heterogeneous in size
(Table I). As the light scattering intensity is proportional
to the sixth power of the particle radius, the size average of
the protein sample is overestimated (26,27). The strong
light scattering of the aggregates inhibits the detection of
the rhIFNβ-1a monomer, which may represent a much
larger fraction by weight than the aggregated material (27).
As the size distributions varied considerably between
repeated measurements, only Z-ave and PDI results are
presented. The Z-ave and PDI of reformulated rhIFNβ-1a
could not be determined due to the small size of the
monomer, the low protein concentration and light-
scattering components in the formulation buffer (i.e.
arginine and Tween 20). Stressed rhIFNβ-1a also contained
aggregates, which were smaller (95 nm) and more homo-
geneous (PDI=0.3) in size than the aggregates in bulk
rhIFNβ-1a. In concordance with our observations from UV
spectroscopy, the addition of 0.01% SDS resulted in a large
decrease in Z-ave (from 2,300 to 27 nm) and PDI (from 0.9
to 0.3) of bulk rhIFNβ-1a, reflecting the dissociation of non-
covalent protein complexes, whereas the mainly covalently
bound aggregates in stressed rhIFNβ-1a stayed intact.
Flow Microscopy
Flow microscopy enables the detection of protein partic-
ulates larger than 0.75 μm that are difficult to study with
1816 van Beers et al.more conventional techniques such as UV, DLS, HP-SEC
and SDS-PAGE. Reformulated rhIFNβ-1a showed a low
particle count that was slightly higher than the particle count
of the buffer control, which was 0.32 × 10
3 particles/ml,
whereas the particle counts of bulk and stressed rhIFNβ-1a
were two orders of magnitude higher (Fig. 1B and Table I).
Particle contents of bulk and stressed rhIFNβ-1a were in the
same range, and both samples had similar size distributions,
mean sizes and mean aspect ratios. Thus, the aggregates
larger than 0.75 μm in bulk and stressed rhIFNβ-1a were
comparable in size, quantity and shape, while such
aggregates were practically absent in reformulated
rhIFNβ-1a.
Fluorescence Spectroscopy
At a wavelength of 295 nm the tryptophans of rhIFNβ-1a
were excited, and a typical emission maximum around
350 nm was observed (Fig. 1C). The wavelength of the
fluorescence peak and its intensity provide information on
the environment of the tryptophan at position 22 (Trp22),
which is close to the receptor binding site and relatively
exposed to the solvent (28,29), and of the tryptophans at
positions 79 and 143, which are both inside the hydropho-
bic core of the protein that is stabilized through several
hydrogen bonds and one disulfide bridge (25,28,29). The
maximum fluorescence intensity of bulk rhIFNβ-1a (at
349 nm) was arbitrarily set at 1, and the fluorescence
intensities of the other samples were calculated relative to
this value (Table I). The fluorescence emission peak of
reformulated rhIFNβ-1a showed a 3 nm red-shift and 14%
increase in intensity in comparison with bulk rhIFNβ-1a,
which may be attributed to the lower degree of aggregation
and more exposed tryptophans (30,31). For comparison,
the spectrum of rhIFNβ-1a unfolded in 6 M guanidine
hydrochloride showed a considerably larger red-shift of
8 nm (Fig. 1C). Stressed rhIFNβ-1a showed a 4 nm blue-
shift and an 8% intensity decrease in the fluorescence
Fig. 1 Graphs showing (A) UV spectra in the absence and presence of 0.01% (w/v) SDS, (B) particle distributions in specified size ranges based on flow
microscopy analysis (with hardly any particles detected in reformulated rhIFNβ-1a), (C) fluorescence emission spectra (with rhIFNβ-1a unfolded in 6 M
guanidine hydrochloride and rhIFNβ-1a heated at 90°C for 10 min, for comparison), and (D) size-exclusion chromatograms, of bulk, reformulated and
stressed rhIFNβ-1a. The HP-SEC peaks (D) are numbered from 1 to 4 (see text for details), with the vertical dashed lines showing the range of each peak.
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tion. The same effect was observed previously by Fan et al.
during heat-induced aggregation of rhIFNβ-1a (32).
Nevertheless, Trp22 in stressed rhIFNβ-1a seems to be
more accessible than a rhIFNβ-1a sample that was
denatured by heating for 10 min beyond its transition
temperature (Fig. 1C). Contrary to the heated sample,
stressed rhIFNβ-1a probably retained most of its native
tertiary structure.
High-Performance Size-Exclusion Chromatography (HP-SEC)
Runkel et al. described the use of a TSKgel SW2000 HP-
SEC column with a mobile phase of 100 mM sodium
phosphate and 200 mM NaCl at pH 7.2 to analyze
rhIFNβ-1a and rhIFNβ-1b products with large amounts of
human serum albumin (HSA) (7). HSA is commonly used
in formulations to prevent adsorption of hydrophobic
protein products (7,33,34). The absence of HSA in our
rhIFNβ-1a formulations may explain the low protein
recovery of our samples in this HP-SEC procedure, i.e.
42% for bulk, 81% for reformulated and 61% for stressed
rhIFNβ-1a (data not shown). Therefore, to inhibit adsorp-
tion of the protein to the solid phase and increase
resolution, we added 0.1% SDS to our mobile phase
(35,36). This resulted in improved recoveries of 87% for
bulk, 93% for reformulated and 71% for stressed rhIFNβ-
1a. The SDS in our elution buffer disrupts non-covalently
bound protein complexes, and it hinders molecular weight
calibration with standard proteins, so we numbered the
different peaks as Peak 1–4 in order of elution (Fig. 1D).
Most bulk rhIFNβ-1a eluted in Peak 3 (50%), which is most
likely the rhIFNβ-1a monomer (Table I). Another signifi-
cant amount eluted in Peak 4 (19%), probably consisting of
monomeric proteins of which the hydrophobic cores are
slightly exposed, causing interactions with the column
material. Peak 1 (8%) of the bulk sample eluted in the void
volume of the column corresponding to soluble protein
aggregates with a molecular weight higher than 150 kDa.
The protein fraction in Peak 2 (10%) is probably a dimer,
which has been reported before (7,25). The non-recovered
fraction comprised 13% of the bulk sample and probably
contained covalent aggregates too large to enter the column
or unfolded protein irreversibly attached to the column
material. The reformulated sample contained 83% mono-
mers, and its total sample recovery was high (93%). The
majority of the stressed sample eluted in the higher molecular
weight regions (31% in Peak 1 and 21% in Peak 2) and
contained a non-recovered fraction of 29%.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS-PAGE)
We applied denaturing polyacrylamide gel electrophoresis
to assess the relative molecular masses of rhIFNβ-1a
monomer, fragments, and covalent aggregates (37). Under
non-reducing conditions, bulk rhIFNβ-1a contained mono-
mer, dimer, trimer and larger aggregates (Fig. 2A, lane B).
The additional band at approximately 19.5 kDa most likely
corresponds with a deglycosylated, monomeric form of
rhIFNβ-1a (7,38). Under reducing conditions, the mono-
mer and dimer showed a slight increase in apparent mass,
Method Parameter Bulk Reformulated Stressed
UV OD280/OD260 1.12 1.67 1.01
OD280/OD260 with SDS
a 1.74 1.76 1.06
OD350 nm 0.11 0.02 0.08
OD350 nm with SDS
a 0.01 0.01 0.06
DLS Z-ave (nm) 2300 ND
b 95
Z-ave with SDS
a (nm) 27 ND
b 120
PDI 0.9 ND
b 0.3
PDI with SDS
a 0.3 ND
b 0.3
Flow microscopy Mean size (ECD
c; μm) 3.0 3.3 2.7
Total particle count (× 10
3/ml) 190 0.82 134
Mean aspect ratio (0–1) 0.67 0.70 0.68
Fluorescence Emission maximum (nm) 349 352 345
Relative peak intensity 1.00 1.14 0.92
HP-SEC
d Fraction peak 1 (%) 8 0 31
Fraction peak 2 (%) 10 6 21
Fraction peak 3 (%) 50 83 14
Fraction peak 4 (%) 19 4 5
Unrecovered fraction (%) 13 7 29
Table I Overview of the
Physicochemical Characteristics
of Bulk, Reformulated and
Stressed rhIFNβ-1a
a0.01% (w/v) SDS was added to
the rhIFNβ-1a preparations before
analysis
bND: not detectable (see text
for details)
cECD: equivalent circular diameter
dFractions were calculated from the
area under the curve (AUC) for
each peak and an extinction
coefficient (E1cm
0:1%) of 1.5
for rhIFNβ-1a (19). Peak
numbers correspond with the
numbers shown in Fig. 1D.
1818 van Beers et al.which is probably due to the breaking of the intramolecular
disulfide bridge of rhIFNβ-1a (Fig. 2B, lane B). The
decreased intensity of the dimer band observed under these
conditions indicates that at least some of the dimers in bulk
rhIFNβ-1a were formed through disulfide bonds. The
covalent trimers and larger aggregates were non-disulfide
mediated.
For reformulated rhIFNβ-1a, non-reducing SDS-PAGE
showed monomers and dimers without any trimers or
larger aggregates, similar to what was seen by HP-SEC (cf.
Fig. 1D and Fig. 2A, lane R). Reducing SDS-PAGE
showed that the dimers in reformulated rhIFNβ-1a were
mainly formed through disulfide bridges (Fig. 2B, lane R).
Under non-reducing conditions, stressed rhIFNβ-1a was
hardly able to enter the gel due to its high percentage of
covalent aggregates (Fig. 2A, lane S). Reducing SDS-PAGE
showed that the aggregates contained reducible bonds, as is
clear from the monomers, dimers and trimers observed
(Fig. 2B, lane S). Non-reducing SDS-PAGE (Fig. 2A)
confirms the proposed nature of the various peaks observed
during HP-SEC (Fig. 1D).
Western Blotting
The polyclonal anti-rhIFNβ-1a antibodies used for Western
blotting reacted with the monomeric bands in all three
rhIFNβ-1a products under both non-reducing and reducing
conditions, including the barely visible monomeric band of
stressed rhIFNβ-1a under non-reducing conditions
(Figs. 2C and 2D). Also, dimers, trimers and larger
aggregates in bulk rhIFNβ-1a and dimers in reformulated
rhIFNβ-1a were recognized by the antibodies under non-
reducing conditions (Fig. 2C). In contrast, none of the non-
reducible covalent protein complexes in bulk, reformulated
or stressed rhIFNβ-1a were recognized by the antibodies
(Fig. 2D), suggesting the destruction of specific epitopes
upon formation of covalent links between monomers.
Summary
Bulk rhIFNβ-1a was shown to contain monomeric protein
and a low amount of heterodisperse rhIFNβ-1a aggregates
with sizes ranging from dimers to aggregates of several
micrometers. The aggregates were mainly formed through
non-covalent bonds and disulfide linkages, and contained
intact epitopes. In addition, some covalent, non-reducible
aggregates were present that were not recognized by the
polyclonal antibody used for Western blotting.
Reformulated rhIFNβ-1a showed low aggregate levels,
mainly dimers containing intact epitopes.
Stressed rhIFNβ-1a contained a high percentage of
rather homogeneously sized covalent aggregates with a size
of approximately 100 nm. Importantly, the covalent non-
reducible aggregates did not contain detectable native
epitopes.
Immunogenicity
In order to test the immunogenicity of the three rhIFNβ-1a
samples, the same schedule of injections was used as before
(8,10,17,20). Fig. 3 shows the levels of IgG antibodies in
wild-type and transgenic mice injected with the three
different products. Please note that the presented BAB
titers on days 4, 11 and 18 in the mice treated with bulk,
reformulated and stressed rhIFNβ-1a might be under-
estimated due to low levels of rhIFNβ-1a in these samples.
In general, the wild-type mice started to produce BABs
between day 4 and day 11 and developed high IgG titers
against all products. These high BAB levels persisted in the
wild-types. With the exception of two mice that did not
Fig. 2 SDS-PAGE gels under (A) non-reducing and (B) reducing
conditions and the corresponding Western blots of the gels under (C)
non-reducing and (D) reducing conditions of the three structural variants
of rhIFNβ-1a. Numbers on the left represent band positions (in kDa) of
the molecular weight markers. Lane B=bulk rhIFNβ-1a; R=reformulated
rhIFNβ-1a; and S=stressed rhIFNβ-1a.
Aggregated rhIFNβ Induces Antibodies but No Memory 1819Fig. 3 Immunogenicity of (A, B) Betaferon®, (C, D) bulk rhIFNβ-1a, (E, F) reformulated rhIFNβ-1a, and (G, H) stressed rhIFNβ-1a. Titers of total IgG
against rhIFNβ in plasma of (A, C, E and G) wild-type (WT) and (B, D, F and H) transgenic (TG) mice injected daily, from Monday to Friday, i.p. with
Betaferon® or one of the rhIFNβ-1a preparations for three weeks starting at day 0. Non-responders were given anarbitrary titer of 1. The legend shows the
NAB status of the individual mice in the treatment group at day 77, with (+) positive for NABs, (−) negative for NABs, (†) died before day 77, and (nd) not
determined. Seven out of 64 mice died during the study due to handling or other reasons, such as liver or heart problems. There were no signs of
anaphylactic responses.
1820 van Beers et al.respond to reformulated rhIFNβ-1a, the wild-type mice also
developedNABsagainsttheproducts(Fig.3A, C, E, and G).
The formation of both BABs and NABs in these animals
indicated that the native protein conformation in all
preparations was at least partly intact.
Transgenic mice, on the other hand, did not develop
NABs against any of the products (Fig. 3B, D, F, H).
Betaferon®, used as a positive control, broke the immune
tolerance of the transgenics but did not induce NAB
formation (Fig. 3B), in keeping with previous observations
(17,20). Three out of seven transgenic mice treated with
bulk rhIFNβ-1a showed low IgG titers at a single time point
(Fig. 3D), indicating a low immunogenicity of this material
in transgenic mice. Reformulated rhIFNβ-1a did not break
the immune tolerance of any of the transgenic mice
(Fig. 3F). From the low, transient IgG titers in only two
out of six transgenic mice treated with stressed rhIFNβ-1a,
it followed that the stressed product was hardly immuno-
genic (Fig. 3H).
Some of the transgenic mice showed a wild-type-like
immune response, including NABs and high, persistent IgG
titers. Although they possessed the transgene (as detected by
PCR), they were not expressing hIFNβ and lacked immune
tolerance, as was discussed in our previous publication
describing the hybrid transgenic mouse model (17). The
hIFNβ gene of the transgenic mice is situated behind the
promoter of murine IFNβ, and its expression can be
stimulated upon injection with polyICLC (20). Without
polyICLC injection, hIFNβ expression levels are not
measurably different between wild-type and transgenic
mice. The mice need to be naïve for immunogenicity
testing and therefore cannot be treated with polyICLC
beforehand. Instead, we analyzed the results of individual
transgenic mice for the presence of both (i) NABs and (ii)
IgG titers exceeding 2,000 up to 8 weeks after the first
injection. Based on these two selection criteria, the data of
five transgenic mice (with ID numbers 13, 29, 42, 50 and
54) that showed a wild-type-like immune response were left
Fig. 4 Titers of total IgG against rhIFNβ in individual mice on day 53, 56, 58 or 60 before the rechallenge (before) and at day 77 after the rechallenge
(after) with reformulated rhIFNβ-1a in plasma of wild-type (left) and transgenic (right) mice treated with (A) Betaferon®, (B) bulk rhIFNβ-1a, (C)
reformulated rhIFNβ-1a, and (D) stressed rhIFNβ-1a. Mean titers and titers of individual mice are shown, and non-responders were given an arbitrary
titer of 1. Statistical analyses (unpaired t test, two-tailed) were performed between groups with 100% responders on log10 converted titers. Asterisks
indicate that titers are significantly (p<0.04) higher after the rechallenge than before.
Aggregated rhIFNβ Induces Antibodies but No Memory 1821out, as they would distort our conclusions on the ability of the
rhIFNβ-1asamplestobreakimmunetolerance.Generally,we
observe about 10–20% hybrid hIFNβ transgenic mice in our
studies exhibiting a wild-type-like immune response indepen-
dent of the type of treatment. In the current study, we
identified five outliers out of 32 transgenic mice (16%), i.e.
1/8 rhIFNβ-1b, 1/8 bulk rhIFNβ-1a, 1/8 reformulated
rhIFNβ-1a and 2/8 stressed rhIFNβ-1a treated transgenic
mice. All outliers showed high persistent levels of BABs, and
they produced NABs while the other transgenics did not. The
equal distribution of the outliers among the treatment groups
clearly indicates that the effect is not product-related.
Immunological Memory
Before the rechallenge with reformulated rhIFNβ-1a at day
63, wild-type mice showed high IgG titers (Fig. 4). After the
rechallenge, the wild-type mice showed IgG titers at day 70
that were higher than before the rechallenge, independent
of the treatment group (Fig. 4A–D). Such an enhanced
secondary immune response is characteristic for a T-cell-
dependent immune response typically observed after
vaccination with foreign protein (14,39). Transgenic mice
treated with Betaferon®, however, showed a slight decrease
in BAB level after the rechallenge with reformulated
rhIFNβ-1a, indicating that they had not developed immu-
nological memory for rhIFNβ (Fig. 4A). Also bulk,
reformulated and stressed rhIFNβ-1a-treated transgenics
did not show any BABs after the rechallenge, indicating the
absence of memory (Fig. 4B–D).
These results comply with the lack of antibody response
observed in patients who, after a wash-out period, switched
to Avonex®-rhIFNβ-1a treatment after having developed
high levels of anti-rhIFNβ-1b antibodies following Beta-
feron® treatment (15). Despite the cross-reactivity of anti-
rhIFNβ antibodies, levels of pre-occurring BABs or NABs
in patients did not increase after switching the treatment
from Betaferon® to Avonex® (15,40), from rhIFNβ-1a to
high-dose intravenous rhIFNβ-1b (41), and from 1.6 to
8 million international units of rhIFNβ-1b (42), without a
wash-out period. Especially patients with low titers may even
reconvert to antibody negativity while treatment continues,
independent of the type of rhIFNβ that is administered
(40,43–46). The observed lack of immunological memory in
immune-tolerant mice as well as in RR-MS patients may be
characteristic for the breakage of B-cell tolerance for
recombinant human therapeutic proteins.
FINAL REMARKS AND CONCLUSIONS
Bulk rhIFNβ-1a, which contained mainly non-covalently
bound aggregates, induced a transient immune response in
approximately 40% of the transgenic mice. Filtration of the
bulk product reduced the aggregation level, and reformu-
lation in another buffer prevented the formation of new
aggregates, thereby completely abolishing its potency to
break immune tolerance. Despite the high percentage of
aggregates in stressed rhIFNβ-1a, only about 30% of the
transgenic mice receiving this product showed antibodies
against rhIFNβ-1a. This is possibly explained by the
absence of native epitopes in the covalent non-reducible
aggregates as shown by Western blotting. Preservation of
the native structure of the protein is a prerequisite for
aggregates to break the tolerance of transgenic, immune-
tolerant mice (8). In addition to BABs, the wild-type mice
formed NABs and immunological memory for the protein
after 3-week administration of any of the rhIFNβ-1a
samples or Betaferon®. This study confirms that wild-type
animals cannot be used to study the immunogenicity of
human therapeutic proteins, and immune-tolerant animal
models are needed (47). In this paper, transgenic mouse
models showed that protein aggregates are able to break
the immune tolerance for rhIFNβ. The potency of the
aggregates to break tolerance not only depends on
aggregate percentage but also largely on their physical
properties such as degree of denaturation, molecular
orientation and size. Moreover, we demonstrated that the
breaking of immune tolerance for rhIFNβ in transgenic
mice is characterized by the absence of NABs and
immunological memory and thereby differs substantially
from a classical T-cell-dependent immune response.
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